Put data ahead of dogma.
Follow the data, not Mr Trump…….

“Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit.”
“….the safety and benefit of these treatment regimens are poorly evaluated in COVID-19.”

“We did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19.”
.
“The registry comprised data from 671 hospitals in six continents. We included patients hospitalised between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2.”
.
“14,888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81,144 patients were in the control group.”
.
“We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide…..”
.
“Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias…..”
.
M.R.Mehra, et al
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
The Lancet [online] — May 22, 2020
.
.
“No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019. Remdesivir…….”

“We did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults admitted to hospital with laboratory-confirmed SARS-CoV-2 infection…..”
.
“Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions) or the same volume of placebo infusions for 10 days.”
.
“Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo)….”
.
“Adverse events were reported in 102 (66%) of 155 remdesivir recipients…..”
.
“Remdesivir was stopped early because of adverse events…..”
.
“In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits.”
.
Y.Wang, et al
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

The Lancet — Volume 395 #10236 — May 16 – 22, 2020 — page 1569
.
.
.
“In God we trust…Everyone else must bring data.” —[W.Edwards Deming]
.
“Most drugs are only effective for a small percentage of people who take them.”
[Michael Leavitt….U.S. Secretary of Health & Human Services 2005 – 2009]